93232-55-4Relevant articles and documents
De novo design of nonpeptidic compounds targeting the interactions between interferon-α and its cognate cell surface receptor
Bello, Angelica M.,Bende, Tanushree,Wei, Lianhu,Wang, Xiaoyang,Majchrzak-Kita, Beata,Fish, Eleanor N.,Kotra, Lakshmi P.
, p. 2734 - 2743 (2008/12/22)
Type 1 interferons (IFN) bind specifically to the corresponding receptor, IFNAR. Agonists and antagonists for IFNAR have potential therapeutic value in the treatment of viral infections and systemic lupus erythematosus, respectively. Specific sequences on